2545-26-8

Basic information

• Product Name: 6-Iodopurine
• Synonyms: 6-IODOPURINE;6-Iodo-9H-purine;1H-Purine, 6-iodo-;6-Iodo-1H-purine;6-Iodo-7H-purine
• CAS NO: 2545-26-8
• Molecular Formula: C₅H₃IN₄
• Molecular Weight: 246.01
• EINECS: 219-825-4
• Product Categories: Pyridines, Pyrimidines, Purines and Pteredines;Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;New Products for Chemical Synthesis;Purines
• Mol File: 2545-26-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 490.4 °C at 760 mmHg
• Flash Point: 250.4 °C
• Appearance: /
• Density: 2.374g/cm³
• Vapor Pressure: 2.76E-09mmHg at 25°C
• Refractive Index: 1.835
• Storage Temp.: 2-8°C
• PKA: 7.54±0.20(Predicted)
• CAS DataBase Reference: 6-Iodopurine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Iodopurine(2545-26-8)
• EPA Substance Registry System: 6-Iodopurine(2545-26-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• RTECS: UO8560000
• Hazardous Substances Data: 2545-26-8(Hazardous Substances Data)

Usage

General Description

6-Iodopurine is a halogenated form of purine, a type of nitrogen-containing compound found in DNA and RNA. As the name suggests, the iodine atom in 6-Iodopurine replaces the hydrogen atom of the purine molecule at the 6th position. It's often utilized in biological and biochemical research studies due to its radiolabeled form that serves as a useful tracer. 6-Iodopurine plays a significant role in medical research, particularly in the fields of genetics and cancer research, where it helps gauge DNA repair and mutation rates. Also, it poses potential cytotoxic effects and is known to induce mutations, thereby inhibiting cell growth and replication.

InChI:InChI=1/C5H3IN4/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H,7,8,9,10)

Upstream product

• 87-42-3 6-chloropurine 
• 87-42-3 6-chloro-7H-purine 

Downstream Products

• 120503-37-9 6-iodo-9-(2,3-dideoxy-β-D-glycero-pentofuranosyl)-9H-purine 
• 83135-13-1 9-benzyl-6-iodo-9H-purine 
• 150721-88-3 7-benzyl-6-iodo-7H-purine 
• 85110-23-2 6-(phenylethynyl)-9H-purine 
• 2036-13-7 7H-purine-6-carbonitrile 
• 756494-16-3 9-[2-deoxy-3,5-di-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-6-iodopurine 
• 5450-35-1 6-(phenylsulfanyl)purine 
• 807626-43-3 3-[9-(2-deoxy-β-D-erythro-pentofuranosyl)purin-6-yl]-2-[(benzyloxycarbonyl)amino]propanoic acid 
• 807626-45-5 (S)-3-[9-(2-deoxy-β-D-erythro-pentofuranosyl)purin-6-yl]-2-[(benzyloxycarbonyl)amino]propanoic acid 
• 787550-85-0 benzyl 3-[9-(3,5-di-O-p-toluoyl-2-deoxy-β-D-erythro-pentofuranosyl)purin-6-yl]-2-[(benzyloxycarbonyl)amino]propanoate 
• 807626-41-1 benzyl (S)-3-[9-(3,5-di-O-p-toluoyl-2-deoxy-β-D-erythro-pentofuranosyl)purin-6-yl]-2-[(benzyloxycarbonyl)amino]propanoate 
• 25491-56-9 9-benzyl-9H-purine 
• 1228040-64-9 methyl 3-(6-iodo-9H-purin-9-yl)-2-(tritylamino)propanoate 
• 1093100-49-2 N₅-(5-(9H-purin-6-yl)pyrimidin-4-yl)-N₁-(4-chlorophenyl)-6-methylisoquinoline-1,5-diamine 

Relevant articles and documents

9-Sulfonyl-9(H)-Purine Derivatives Inhibit HCV Replication Via their Degradation Species

Cell-based screening of a privileged small molecule library led to the discovery of 9-sulfonyl-9(H)-purine as new scaffold for hepatitis C virus (HCV) inhibitors. Structure–activity relationship study with respect to the 2-, 6- and 9-positions in the purine core resulted in the identification of several active compounds with moderate potency against the HCV genotype 1b. Subsequent stability studies demonstrated that HCV inhibitors of this type were unstable in Dulbecco’s modified eagle medium (DMEM) and plasma, as well as glutathione-containing water, and their instability was closely related to their HCV inhibitory activity. A preliminary study of the mechanism of action showed that the sulfonamide bond at the 9-position of purine would be the primary degradation site and the resulting sulfonylation degradation species would mediate the anti-HCV activity of 9-sulfonyl-9(H)-purines. Results of this study demonstrated that 9-sulfonyl-9(H)-purine is an unstable scaffold for HCV inhibitors and further detailed analysis of the degradation species is needed to determine the main active components and direct target for this type of molecules.

FUSED HETEROARYL PYRIDYL AND PHENYL BENZENESUFLONAMIDES AS CCR2 MODULATORS FOR THE TREAMENT OF INFLAMMATION

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2- mediated diseases and as controls in assays for the identification of CCR2 antagonists. A compound of the formula (I) or a salt thereof: where: R1 and R2 are each independently hydrogen, halogen, C1-8alkyl, -CN. or C1-8 haloalkyl, provided that at least one of R11or R2 is other than hydrogen; each R3 is independently hydrogen; R4 is hydrogen; R5 is halogen or C1-8 alkyl; R6 is hydrogen; X1 is CR7, N or NO; X2 and X4 are N or NO; X3 is CR7; X6 and X7 are each independently selected from CR7, N, and NO; each R7 is independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C2-8 alkyl, substituted or unsubstituted C2-8 alkeπyl, substituted or unsubstituted C2-8 alkynyl, -CN. =O, -NO2, -OR6, -OC(O)R8, -CO2R8, -C(O)R8, -C(O)NR0R8, -OC(O)NR9R8, -NR10C(O)R8, -NR10C(O)NR9R8, -NR9R8, -NR10CO2R8, -SR8, -S(O)R8, -S(O)2R8, -S(O)2NR9R8, -NR10S(O)2R8, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl and substituted or unsubstituted 3- to 10-membered heterocyclyl;